Application of inhibiting ALKBH5 in treating pulmonary arterial hypertension caused by hypoxia

• Main Authors: HE YUANJIE, SHI BEI, DENG YI, ZHAO YONGCHAO, ZHAO RANZUN, GU NING, SHIN YOU-SEUNG, ZHANG WEI
• Format: Patent
• Language: Chinese; English
• Published: 03.01.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the technical field of biological medicines, and discloses application of ALKBH5 inhibition in treatment of pulmonary arterial hypertension caused by hypoxia, and application of ALKBH5 inhibition gene or protein in treatment of pulmonary arterial hypertension caused by hypoxia. Through the application of inhibiting the ALKBH5 gene or protein, the phenotypic transformation of the hypoxia-induced pulmonary artery smooth muscle cells and the pulmonary hypertension can be obviously improved, and a new target is provided for treating the pulmonary hypertension caused by hypoxia. 本发明属于生物医药技术领域，公开了抑制ALKBH5在治疗缺氧所致肺动脉高压中的应用，抑制ALKBH5基因或蛋白应用在治疗缺氧所致肺动脉高压中。通过对抑制ALKBH5基因或蛋白的应用，可显著改善缺氧诱导的肺动脉平滑肌细胞表型转化和肺动脉高压，为治疗缺氧所致肺动脉高压提供了新的靶点。